WSJ -- Two venture-backed companies are developing protective therapies that could serve as a stopgap in case there isn’t time to wait for vaccines to be developed against swine flu or a similar outbreak of infectious disease.
WSJ -- Two venture-backed companies are developing protective therapies that could serve as a stopgap in case there isn’t time to wait for vaccines to be developed against swine flu or a similar outbreak of infectious disease.
